Introduction
============

Spontaneous bacterial peritonitis (SBP) is one of the common complications in liver cirrhosis (LC) patients with ascites ([@b1-etm-0-0-7502]). Several mechanisms contribute to the occurrence of SBP, including translocation of gut bacteria and their products, reduction of intestinal motility provoking bacterial overgrowth, alteration of the gut\'s barrier function and local immune responses ([@b2-etm-0-0-7502]). The occurrence of SBP in hospitalized ascites patients range from 10--30% ([@b3-etm-0-0-7502]). Furthermore, SBP secondary to LC frequently aggravates liver damage and induces serious complications, including hepatorenal syndrome and hepatic encephalopathy ([@b4-etm-0-0-7502]). Therefore, early diagnosis and effective treatment are vital to improve the clinical outcome.

The clinical manifestations of SBP range from asymptomatic to typical peritoneal infection and even to severe hepatic encephalopathy or hepatorenal syndrome, easily leading to a missed diagnosis and misdiagnosis. Diagnostic puncture frequently has an important role in the diagnosis of SBP ([@b5-etm-0-0-7502]). In a previous study, the diagnosis was based on bacterial positive cultures in ascitic fluid and/or the testing of an elevated absolute fluid polymorphonuclear neutrophil (PMN) count in the ascites (\>250/mm^3^) without any obvious abdominal intra-operatively detected source of infection ([@b6-etm-0-0-7502]).

In recent years, with the prevalence of multidrug-resistant bacteria and the re-distribution of the bacterial spectrum, SBP has become a serious clinical problem in several countries. In addition, a variation in the epidemiology of bacteria, which may be the reason for the increased prevalence of SBP, was reported in patients with long-term norfloxacin prophylaxis, appearing in the quinolone-resistant bacterial culture, as well as Gram-positive bacteria (GPB) ([@b7-etm-0-0-7502]). Numerous studies have focused on the therapeutic effects of various antibiotics and suggested that their efficacy is associated with SBP infection strains. A recent analysis determined that the rate of third-generation cephalosporin resistance ranged from 15.6--44.0% in SBP cases ([@b8-etm-0-0-7502]). In conclusion, the selection of effective antibiotics according to the type of pathogen it is crucial for SBP patients.

The present study aimed to retrospectively examine changes in the bacterial spectrum, laboratory characteristics and drug resistance in LC patients with SBP. The results may contribute to the understanding of the etiologic features of SBP and may provide guidance for the selection of medication for empirical treatment.

Materials and methods
=====================

### Subjects

A total of 3, 189 patients with ascites, including 912 LC patients, of which 247 had SBP, who had been admitted to Beijing Di Tan Hospital, Capital Medical University (Beijing, China) between January 2011 and December 2016 were retrospectively enrolled in the present study. Patients with ascites were assigned to Group A (admission, 2011--2013) and Group B (admission, 2014--2016). Patients with LC were assigned to Group A1 (admission, 2011--2013) and Group B1 (admission, 2014--2016). Of these, the patients with SBP identified by positive culture were assigned to Group 1 (admission, 2011--2013) and Group 2 (admission, 2014--2016).

All of the patient data were retrospectively retrieved from their electronic health records. The present study was approved by the Ethics Committee of the Beijing Di Tan Hospital (Beijing, China) and was in accordance with the 1975 Declaration of Helsinki.

According to the guidelines published by the American Association for the Study of Liver Diseases ([@b9-etm-0-0-7502]) and the European Association for the Study of the Liver ([@b10-etm-0-0-7502]), the diagnostic standard for SBP was a positive ascitic fluid culture and/or a polymorphonuclear leukocyte count of the ascitic fluid of ≥250 cells/mm^3^.

### Laboratory techniques

The ascitic fluid (10 ml) was collected and inoculated into aerobic and anaerobic blood bottles (BD Biosciences) and cultured at an automated culture system (BACTEC 9240 and FX200; BD Biosciences) at 35°C for up to 5 days prior to being reported as negative. After a positive signal was obtained on the instrument, the cells were smeared and inoculated on a blood agar, and cultivated at 35°C. These cultivated bacteria were identified with the BD Phoenix™ automated identification and susceptibility testing system (BD Biosciences).

### Statistical analysis

All data were analyzed using SPSS 19.0 software (IBM Corp.). The patients\' features were assessed using the median (interquartile range) for continuous variables and n (%) for categorical variables. The Mann-Whitney U-test and chi-square test were used for continuous and categorical variables, respectively. A two-sided P\<0.05 was considered to indicate statistical significance.

Results
=======

### Patient characteristics at baseline

Among the 912 patients, SBP was detected in 247 (27.1%), while the remaining 665 (72.9%) were without SBP. The mean age of the 912 patients (681 males and 231 females) was 56.3±11.9 years. The most general chronic underlying diseases included diabetes in 207 cases (22.7%), high blood pressure in 190 cases (20.8%), coronary heart disease in 15 cases (1.6%) and alcoholic hepatitis, which was not viral hepatitis, in 260 cases (28.5%). The most general cause of LC was viral hepatitis, which was identified in 717 patients (78.6%), including hepatitis B in 139 patients (73.3%), hepatitis C in 17 (9.4%) and hepatitis B + C in 3 patients (1.7%). In addition, among the SBP patients, primary biliary hepatitis was identified in 6 patients (3.3%), autoimmune hepatitis in 6 patients (3.3%) and other types of hepatitis in 9 patients (5.0%). On the other hand, among the patients without SBP, hepatitis B was present in 410 patients (68.9%), hepatitis C in 49 patients (9.10%) and Hepatitis B + C in 9 patients (1.7%). Furthermore, among the patients without SBP, primary biliary hepatitis was present in 19 patients (3.5%), autoimmune hepatitis in 16 patients (3.0%) and other types of hepatitis in 34 patients (6.3%). The ratios were similar between the groups with SBP and without SBP ([Table I](#tI-etm-0-0-7502){ref-type="table"}).

### SBP ratios in ascites patients and cirrhotic patients

As presented in [Fig. 1](#f1-etm-0-0-7502){ref-type="fig"}, the SBP ratios in patients with ascites and cirrhotic increased between 2011 and 2016, with a rising trend observed between 2014 and 2015. Since 2014, as the popularity of the hospital increased, the number of patients substantially increased. Hence, the 3, 189 patients with ascites were divided into two observation groups: Group A, containing 52 SBP patients from the 765 patients with ascites admitted between 2011 and 2013, and Group B, containing 195 SBP patients from the 2, 424 patients with ascites admitted between 2014 and 2016. The patients in Group A and Group B did not distinctly differ regarding their epidemiological and clinical features. However, the laboratory results of the bacterial culture between the two groups were significantly different, i.e., they were distinctly lower in Group A than in Group B (P=0.009; [Table II](#tII-etm-0-0-7502){ref-type="table"}). The 912 LC patients were divided into two observation groups: Group A1, containing 52 SBP patients from the 271 patients with cirrhosis admitted between 2011 and 2013, and Group B1, containing 195 SBP patients from the 641 patients with cirrhosis admitted between 2014 and 2016. The results demonstrated that the ratio of SBP in Group B and Group B1 were higher than those in Group A and Group A1, respectively.

### Laboratory results of plasma and ascitic fluid analysis in Groups 1 and 2

The results of the laboratory analyses of plasma and ascitic fluid were compared between Group 1 (SBP; 2011--2013) and Group 2 (SBP, 2014--2016). The laboratory results for Group 1 and Group 2 were not distinctly different, except for direct bilirubin \[21.75 (6.43, 63.90) vs. 28.80 (13.30, 77.50), P=0.034\], C-reactive protein (CRP) in the plasma \[28.63 (10.78, 61.88) vs. 44.50 (18.36, 87.88), P=0.018\] and positive bacterial culture of ascitic fluid \[21 (8.50%) vs. 118 (47.5%), P=0.009\]; these values were distinctly lower in Group 1 compared with those in Group 2 ([Table II](#tII-etm-0-0-7502){ref-type="table"}).

### Classification of total bacteria

As presented in [Fig. 2](#f2-etm-0-0-7502){ref-type="fig"}, during the retrospective enrolment period, a total of 247 patients were diagnosed with SBP, and the total number of bacterial strains obtained from the positive culture of ascitic fluid was 139. In addition, the number of bacteria detected in Group 1 (21 strains) was markedly lower than that in Group 2 (118 strains). Furthermore, the rate of infection with GPB was markedly higher in Group 2 than that in Group 1 \[10/21 (48%) vs. 63/118 (53.4%); [Fig. 2B](#f2-etm-0-0-7502){ref-type="fig"}\]. Over time, GPB and gram-negative bacteria (GNB) were increased, while the increase of GPB was greater than that of GNB ([Fig. 2A and B](#f2-etm-0-0-7502){ref-type="fig"}).

The strains obtained from the ascitic fluid of patients during the whole term of the study (2011--2016) are presented in [Fig. 2C and D](#f2-etm-0-0-7502){ref-type="fig"}. Among the bacteria in ascitic fluid, 139 species were identified, of which 66 (47.5%) were GPB and 73 (52.5%) were GNB. Among the GNB, *Escherichia coli* was the most common isolated stain (26 out of 66 cases, 39.4%), followed by *Klebsiella pneumonia* (12 cases, 18.2%), *Enterobacter cloacae* (7 cases, 10.6%), *Pseudomonas aeruginosa* (5 cases, 7.6%), *Acinetobacter baumannii* and *Citrobacter* (3 cases, 4.6%, respectively), as well as *Enteroaerogen, Klebsiella* acid bacteria, *Aeromonas hydrophila* and *Pseudomonas* (2 cases, 3.0%, respectively), *Alcaligenes* and *Salmonella* (1 case, 1.5%, respectively). The GPB comprised *Streptococcus* (17 cases, 23.3%), as well as *Enterococcus* and *Staphylococcus* species (28 cases, 38.3%, respectively).

### Laboratory results of cirrhotic patients with culture-positive SBP compared between GNB and GPB

The 73 SBP patients with GPB, compared with the 66 SBP patients with GNB, were discovered to have decreased mean plasma ALT \[23.5 (15.0, 56.2) vs. 41.1 (21.2, 73.1), P=0.001\] and AST \[38.5 (24.3, 75.9) vs. 62.0 (29.3, 139.9), P=0.004\] levels, and a greater prothrombin time \[international normalized ratio, 4.49 (1.30, 1.87) vs. 1.38 (1.21, 1.60), P=0.011\]. Furthermore, SBP patients with GPB, compared with those with GNB, had an obviously lower median ascitic white blood cell count \[884.0 (173.0, 6891.8) vs. 1, 973.0 (937.8, 3, 913.0), P=0.002\], PMN \[362.6 (43.2, 5, 040.0) vs. 1232.2 (498.8, 2, 557.5), P=0.001\] and albumin \[6.20 (4.15, 10.20) vs. 8.60 (4.58, 16.63), P=0.008; [Table III](#tIII-etm-0-0-7502){ref-type="table"}\].

### In-hospital complications and different pathogenies compared between GNB and GPB

Comparison of the in-hospital complications and different pathogenies revealed significantly higher alcoholic hepatitis (18.18 vs. 35.62, P=0.042) and Splenauxe (10.61 vs. 27.40, P=0.008), as well as lower constipation (0.001 vs. 9.09, P=0.020) in subjects with GPB vs. GNB ([Table IV](#tIV-etm-0-0-7502){ref-type="table"}).

### Antibiotic resistance of GNB and GPB strains

In the present study, *Escherichia coli* (GNB) and coagulase-negative *Staphylococcus* (GPB) were the major pathogens in SBP. Furthermore, 16 *Escherichia coli* strains and 12 *Klebsiella pneumonia* strains were extended-spectrum β-lactamase-positive ([Table V](#tV-etm-0-0-7502){ref-type="table"}). The resistance rate of *Staphylococcus aureus* (n=8) and coagulase-negative *Staphylococcus* (n=20) to penicillin (ampicillin) was 100% ([@b8-etm-0-0-7502],[@b20-etm-0-0-7502]), while the corresponding rate for vancomycin, teicoplanin, amikacin and linezolid was 0%, which was consistent with recommendations provided by the Clinical Laboratory Standards Institute ([@b11-etm-0-0-7502]).

Discussion
==========

SBP is a general and severe complication of LC patients with ascites. It remains to be associated with a significant amount of mortality, in spite of recent improvements in curative approaches ([@b12-etm-0-0-7502]). It is generally accepted that an intestinal GNB flora, particularly *Enterobacteriaceae*, is the major cause of SBP ([@b13-etm-0-0-7502]). However, a number of studies have indicated that the proportion of GPB in SBP was increased even more than that of GNB ([@b2-etm-0-0-7502],[@b14-etm-0-0-7502],[@b15-etm-0-0-7502]). Furthermore, the emergence of multidrug-resistant bacteria and the variation in the epidemiology of bacteria may lead to failure of the first-line empirical treatment program, thereby posing great challenges ([@b16-etm-0-0-7502]). In view of the complexity of SBP strains and the dependence on empirical treatment, the present study aimed to clarify the changes of the bacterial spectrum in SBP and drug resistance, so as to provide a reliable reference for clinical practice.

In the present study, during the observational period, the number of patients with SBP increased, and the number of bacteria also increased over time. The proportion of GPB increased between 2014--2016 compared with 2011--2013, and was even higher than the proportion of GNB. Since the detection methods and instruments used were the same between 2011 and 2016, there should be no significant difference in detection sensitivity. These results were in coherence with several studies, which reported a high frequency of GPB infection associated with SBP ([@b17-etm-0-0-7502]). Through the analysis of serological and ascites indexes, it was revealed that direct bilirubin, CRP in the plasma and the positive rate of ascites culture in Group 2 were all higher than those in Group 1. This may be attributed to the clinicians paying more attention to patients with cirrhosis compared to patients with SBP, leading to an improved rate of detection.

Next, the laboratory parameters of cirrhotic patients with culture-positive SBP and their in-hospital complications, as well as the pathogeny and complications were compared between GNB and GPB. The results indicated that GPB infection was more likely to occur in alcoholic hepatitis patients, and to be associated with complications of splenauxe and constipation, while GNB infection caused more serious liver damage and severe abdominal infection. Therefore, the results of the present study suggested that clinicians should pay attention to the possibility of GPB infection in alcoholic hepatitis patients with SBP, and to consider taking measures to prevent splenauxe and constipation in SBP patients with GPB infection. In addition, for SBP patients with GNB infection, it is essential to keep a watchful eye on the occurrence of liver damage.

Furthermore, the antibiotic resistance of GPB and GNB was assessed. The results on drug sensitivity revealed that the resistance rate of GPB and GNB to penicillin (ampicillin) was 100%, while the resistance rates to amikacin, imipenem, meropenem, piperacillin/tazobactam were 0% for GNB, and the resistance rates to vancomycin, teicoplanin, amikacin and linezolid were 0% for GPB. These results indicate that the antibiotics to be appliedmay in part be determined based on the bacterial strains involved in SBP in individual patients. The reported percentage of drug resistance of major pathogenic bacteria to antibiotics recommended as first-line medications by guidelines is relatively high ([@b10-etm-0-0-7502],[@b18-etm-0-0-7502],[@b19-etm-0-0-7502]). This may be attributed to the imperfection of the antibiotic management system in China. The results of the present study suggest that the use of acombination of ampicillin/sulbactam or piperacillin/tazobactam as an experiential therapy for SBP patients. In nosocomial cases, the abovementioned drugs should be combined with vancomycin, linezolid or teicoplanin, when required.

The present study has a number of limitations. First, the patients included were from a single unit (Beijing Di Tan Hospital, Capital Medical University, Beijing, China) where the occurrence of HBV associated with chronic kidney disease, LC and hepatocellular carcinoma is high. Furthermore, due to the retrospective nature of the study, a possibility for bias and imprecise data collection may exist. More comprehensive prospective studies using a larger number of cases and involving multiple units may be essential. Furthermore, more samples will be collected to validate this trend in the future. It is imperative that physicians consider all relevant factors when diagnosing and treating patients with cirrhosis and SBP ([@b20-etm-0-0-7502],[@b21-etm-0-0-7502]).

Furthermore, SBP is a severe complication of LC, and all patients should be considered for inchoate diagnosis and curative treatment in order to lower the amount of fatalities ([@b22-etm-0-0-7502]). High vigilance in patients with ascites presenting with acute clinical deterioration is imperative. The present study indicated differences of the laboratory results of Groups 1 and 2, as well as in-hospital complications between patients with GPB and GNB infection. Combined use of ampicillin/sulbactam or piperacillin/tazobactamin experiential therapy is recommended. In nosocomial cases, these drugs should be combined with vancomycin, linezolid or teicoplanin when required. Therefore, it is essential to watch out for changes in respective indicatorsin plasma and ascites, as well as detect pathogens as early as possible to ensure for timely diagnosis and treatment of SBP.
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###### 

Baseline characteristics of the enrolled patients.

  Item                        Total (n=912)   SBP+ (n=247)   SBP- (n=665)
  --------------------------- --------------- -------------- --------------
  Age (years)                 56.3±11.9       55.5±11.4      56.6±12.1
  Male gender                 681 (74.7)      193 (78.1)     488 (73.4)
  Diabetes                    207 (22.7)      52 (21.1)      155 (23.3)
  High blood pressure         190 (20.8)      51 (20.6)      139 (20.9)
  Coronary heart disease      15 (1.6)        5 (2.0)        10 (1.5)
  Cause                                                      
  Alcoholic hepatitis         260 (28.5)      66 (26.7)      194 (29.2)
  Hepatitis B virus           549 (60.20)     139 (56.3)     410 (61.7)
  Hepatitis C virus           66 (7.24)       17 (6.9)       49 (7.4)
  Hepatitis B+C virus         12 (1.32)       3 (1.2)        9 (1.4)
  Primary biliary hepatitis   25 (2.74)       6 (2.4)        19 (2.9)
  Autoimmune hepatitis        22 (2.41)       6 (2.4)        16 (2.4)
  Other hepatitis             43 (4.71)       9 (3.6)        34 (5.1)

Values are expressed as n (%) or the mean ± standard deviation. SBP, spontaneous bacterial peritonitis.

###### 

Laboratory results of patients with spontaneous bacterial peritonitis in plasma and ascitic fluid in Group 1 (n=52, 21.1%) and Group 2 (n=195, 78.9%).

  Parameter                          Group 1                       Group 2                       Reference range   P-value
  ---------------------------------- ----------------------------- ----------------------------- ----------------- ---------
  Male gender                        42                            152                           --                0.939
  Age (years)                        55.00 (49.00, 62.75)          56.00 (47.00, 63.00)          --                0.681
  WBC (10^9^/l)                      7.31 (4.51, 10.97)            8.50 (4.98, 13.29)            4.00--10.00       0.144
  Plasma                                                                                                           
    Albumin (g/l)                    28.95 (25.88, 31.85)          29.20 (26.20, 32.70)          40.00--55.00      0.542
    Total bilirubin (µmol/l)         50.60 (15.43, 101.78)         50.60 (23.80, 117.70)         0.00--18.80       0.308
    Creatinine (µmol/l)              85.85 (67.10, 124.35)         79.00 (62.70, 128.00)         57.00--111.00     0.814
    Sodium (mmol/l)                  134.40 (130.63, 138.35)       134.20 (130.10, 138.10)       137.00--147.00    0.925
    Glucose (mmol/l)                 6.93 (5.54, 8.63)             7.16 (5.47, 9.44)             4.16--6.44        0.578
    Urea (mmol/l)                    8.55 (5.50, 13.26)            9.19 (5.80, 15.00)            1.70--8.30        0.512
    Chloride (mmol/l)                102.00 (94.48, 104.35)        99.00 (94.70, 104.60)         99.00--110.00     0.658
    ALT (U/l)                        41.65 (19.98, 60.05)          29.60 (16.00, 60.30)          9.00--50.00       0.145
    AST (U/l)                        60.30 (28.65, 130.95)         42.80 (25.00, 92.20)          15.00--40.00      0.092
    Direct bilirubin (µmol/l)        21.75 (6.43, 63.90)           28.80 (13.30, 77.50)          0.00--6.80        0.034
    Total protein (g/l)              58.95 (52.28, 67.48)          58.90 (51.80, 65.20)          65.00--85.00      0.781
    Total bile acid (µmol/l)         28.05 (16.28, 61.78)          36.10 (8.20, 102.60)          0.00--10.00       0.784
    Prothrombin time (sec)           16.30 (14.20, 19.15)          16.00 (14.00, 19.90)          9.40--12.50       0.847
    Prothrombin time (INR)           1.38 (1.21, 1.55)             1.44 (1.26, 1.81)             0.80--1.20        0.136
    CRP (mg/l)                       28.63 (10.78, 61.88)          44.50 (18.36, 87.88)          0.00--5.00        0.018
  Ascites                                                                                        --                
    WBC (cells/µl)                   1,771.00 (450.00, 3,195.00)   1,515.00 (600.00, 6,127.00)   --                0.741
    PMN (cells/µl)                   1,077.10 (279.70, 2,494.00)   800.00 (120.12, 4,262.65)     --                0.931
    Kalium (mmol/l)                  3.79 (3.44, 4.29)             3.93 (3.36, 4.47)             --                0.977
    Sodium (mmol/l)                  134.60 (131.30, 139.00)       134.30 (129.80, 139.40)       --                0.485
    Chloride (mmol/l)                106.90 (99.20, 110.30)        104.80 (98.10, 110.00)        --                0.315
    Glucose (mmol/l)                 7.78 (6.51, 8.79)             7.70 (6.28, 9.75)             --                0.538
    Albumin (g/l)                    9.20 (4.20, 17.00)            7.10 (4.40, 11.80)            --                0.260
    Positive ascitic fluid culture   21 (8.50)                     118 (47.5)                    --                0.009
    In-hospital mortality            12 (4.86)                     37 (14.98)                    --                0.511

Values are expressed as n (%) or median (interquartile range). Groups: 1, ascites patients with liver cirrhosis and SBP admitted between 2011 and 2013; 2, ascites patients with liver cirrhosis and SBP admitted between 2014 and 2016. WBC, white blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; PMN, polymorphonuclear leukocytes; INR, international normalized ratio.

###### 

Laboratory parameters of cirrhotic patients with culture-positive spontaneous bacterial peritonitis compared between Gram-negative bacteria and Gram-positive bacteria.

  Parameter                     Gram-positive bacteria (n=73)   Gram-negative bacteria (n=66)   P-value
  ----------------------------- ------------------------------- ------------------------------- ---------
  WBC (10^9^/l)                 8.07 (4.80, 13.1)               8.49 (4.85, 13.15)              0.633
  Plasma                                                                                        
    Albumin (g/l)               29.3 (26.2, 32.2)               29.0 (26.2, 32.5)               0.600
    Total bilirubin (µmol/l)    51.8 (23.9, 114.2)              50.7 (20.3, 106.8)              0.351
    Creatinine (µmol/l)         87.0 (62.7, 131.2)              77.4 (64.1, 119.5)              0.362
    Sodium (mmol/l)             134.8 (130.6, 138.9)            134.0 (139.8, 137.2)            0.213
    Glucose (mmol/l)            7.25 (5.34, 9.45)               6.94 (5.54, 9.19)               0.606
    Urea (mmol/l)               9.83 (6.21, 15.42)              8.01 (5.74, 13.92)              0.157
    Chloride (mmol/l)           99.3 (95.2, 104.9)              100.4 (93.9, 103.8)             0.780
    ALT (U/l)                   23.5 (15.0, 56.2)               41.1 (21.2, 73.1)               0.001
    AST (U/l)                   38.5 (24.3, 75.9)               62.0 (29.3, 139.9)              0.004
    Direct bilirubin (µmol/l)   28.9 (13.2, 76.1)               25.0 (9.5, 70.6)                0.450
    Total protein (g/l)         58.5 (51.2, 64.9)               60.0 (53.2, 66.8)               0.396
    Total bile acid (µmol/l)    38.4 (10.0, 99.7)               31.5 (11.8, 100.1)              0.873
    Prothrombin time (sec)      16.4 (14.3, 20.4)               16.0 (13.9, 18.9)               0.339
    Prothrombin time (INR)      4.49 (1.30, 1.87)               1.38 (1.21, 1.60)               0.011
    CRP (mg/l)                  47.7 (21.7, 85.5)               43.3 (20.5, 80.5)               0.962
  Ascites                                                                                       
    WBC (cells/µl)              884.0 (173.0, 6,891.8)          1973.0 (937.8, 3,913.0)         0.002
    PMN (cells/µl)              362.6 (43.2, 5,040.0)           1232.2 (498.8, 2,557.5)         0.001
    Kalium (mmol/l)             3.94 (3.34, 4.44)               3.90 (3.43, 4.43)               0.793
    Sodium (mmol/l)             134.8 (129.9, 139.7)            134.2 (130.0, 138.8)            0.712
    Chloride (mmol/l)           105.6 (98.9, 109.8)             105.7 (98.3, 111.0)             0.903
    Glucose (mmol/l)            7.81 (6.60, 9.65)               7.62 (6.27, 9.43)               0.314
    Albumin (g/l)               6.20 (4.15, 10.20)              8.60 (4.58, 16.63)              0.008

Values are expressed as the median (interquartile range). WBC, white blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; PMN, polymorphonuclear leukocytes; INR, international normalized ratio.

###### 

Comparison of in-hospital complications and different pathogenies between Gram-negative bacteria and Gram-positive bacteria.

  Item                                  Gram-positive bacteria (n=73)   Gram-negative bacteria (n=66)   P-value
  ------------------------------------- ------------------------------- ------------------------------- ---------
  Pathogenies, n (%)                                                                                    
    Alcoholic hepatitis                 27 (36.99)                      13 (19.70)                      0.042
    Hepatitis B                         35 (47.95)                      32 (48.48)                      1.000
    Hepatitis C                         3 (4.11)                        5 (7.58)                        1.000
    Hepatitis B + C                     1 (1.37)                        1 (1.52)                        1.000
    Primary biliary hepatitis           0 (0.00)                        3 (4.55)                        1.000
    Autoimmune hepatitis                2 (2.74)                        2 (3.03)                        1.000
  Complications, n (%)                                                                                  
    Reflux esophagitis                  11 (15.07)                      12 (18.18)                      0.348
    Hepatorenal syndrome                14 (19.18)                      19 (28.79)                      0.259
    Hypoproteinemia                     58 (79.45)                      47 (71.21)                      0.354
    Upper gastrointestinal hemorrhage   16 (21.92)                      7 (10.61)                       0.074
    Hepatic encephalopathy              30 (41.10)                      18 (27.27)                      0.088
    Esophagus varix                     25 (34.25)                      18 (27.27)                      0.278
    Esophagus bleeding                  17 (23.29)                      9 (13.64)                       0.228
    Splenauxe                           21 (28.77)                      8 (12.12)                       0.008
    Spleen hyperfunction                32 (43.84)                      25 (37.88)                      0.477
    Gallstone                           11 (15.07)                      9 (13.64)                       0.989
    Cholecystitis                       6 (8.22)                        5 (7.58)                        0.889
    Pulmonary infection                 16 (21.92)                      17 (25.76)                      0.597
    Pleural effusion                    13 (17.81)                      15 (22.73)                      0.472
    Constipation                        1 (1.37)                        7 (10.61)                       0.020
    Gastrohelcosis                      11 (15.07)                      9 (13.64)                       0.588
    Hepatic failure                     17 (23.29)                      17 (25.76)                      0.590
    Chronic renal failure               15 (20.55)                      10 (15.15)                      0.410
    Hyperkalemia                        9 (12.33)                       9 (13.64)                       0.819
    Hypokalemia                         23 (31.51)                      22 (33.33)                      0.819
    Hyponatremia                        7 (9.59)                        8 (12.12)                       0.843
    Anemia                              30 (41.10)                      23 (34.85)                      0.451
    Hemorrhagic shock                   4 (5.48)                        2 (3.03)                        0.802
    Primary hepatic carcinoma           19 (26.03)                      17 (25.76)                      0.971
    Portal hypertension                 7 (9.59)                        7 (10.61)                       0.843
    Metabolic acidosis                  5 (6.85)                        4 (6.06)                        0.851

###### 

Antibiotic resistance of Gram-negative and -positive bacterial strains.

  A, Antibiotic resistance of Gram-negative bacterial strains                                                                                            
  ----------------------------------------------------------------- ----------------------------------- ------------------------------------------------ ------------
  Ampicillin                                                        16 (100.00)                         10 (100.00)                                      12 (75.00)
  Ticarcillin/clavulanic acid                                       3 (18.75)                           0 (0.00)                                         1 (6.25)
  Amikacin                                                          0 (0.00)                            0 (0.00)                                         1 (6.25)
  Aztreonam                                                         7 (43.75)                           0 (0.00)                                         2 (12.50)
  Chloromycetin                                                     8 (50.00)                           0 (0.00)                                         1 (6.25)
  Cefazidime                                                        3 (18.75)                           0 (0.00)                                         2 (12.50)
  Ciprofloxacin                                                     13 (81.25)                          2 (20.00)                                        2 (12.50)
  Cefotaxime                                                        11 (68.75)                          0 (0.00)                                         2 (12.50)
  Cephazolin                                                        15 (93.75)                          1 (10.00)                                        2 (12.50)
  Cefepime                                                          6 (37.50)                           0 (0.00)                                         2 (12.50)
  Gentamicin                                                        7 (43.75)                           0 (0.00)                                         1 (6.25)
  Imipenem                                                          0 (0.00)                            0 (0.00)                                         1 (6.25)
  Levofloxacin                                                      13 (81.25)                          2 (20.00)                                        2 (12.50)
  Meropenem                                                         0 (0.00)                            0 (0.00)                                         1 (6.25)
  Piperacillin                                                      16 (100.00)                         0 (0.00)                                         3 (18.75)
  Ampicillin/sulbactam                                              5 (31.25)                           0 (0.00)                                         2 (12.50)
  SMZ                                                               12 (75.00)                          0 (0.00)                                         3 (18.75)
  Acheomycin                                                        14 (87.50)                          1 (10.00)                                        3 (18.75)
  Piperacillin/tazobactam                                           2 (12.50)                           0 (0.00)                                         1 (6.25)
                                                                                                                                                         
  **B, Antibiotic resistance of Gram-positive bacterial strains**                                                                                        
                                                                                                                                                         
  **Antibiotic, n (%)**                                             ***Staphylococcus aureus* (n=8)**   **Coagulase-negative *Staphylococcus* (n=20)**   
                                                                                                                                                         
  Ampicillin                                                        8 (100.00)                          20 (100.00)                                      
  Ticarcillin/clavulanic acid                                       1 (12.50)                           18 (90.00)                                       
  Amikacin                                                          0 (0.00)                            0 (0.00)                                         
  Clindamycin                                                       1 (12.50)                           6 (30.00)                                        
  Ciprofloxacin                                                     0 (0.00)                            10 (50.00)                                       
  Erythromycin                                                      3 (37.50)                           18 (90.00)                                       
  Macrodantin                                                       0 (0.00)                            19 (95.00)                                       
  Cefoxitin                                                         1 (12.50)                           20 (100.00)                                      
  Gentamicin                                                        0 (0.00)                            9 (45.00)                                        
  Linezolid                                                         0 (0.00)                            1 (5.00)                                         
  Tobramycin                                                        1 (12.50)                           9 (45.00)                                        
  Oxacillin                                                         1 (12.50)                           18 (90.00)                                       
  Penicillin                                                        6 (75.00)                           20 (100.00)                                      
  Rifampicin                                                        0 (0.00)                            16 (80.00)                                       
  SMZ                                                               1 (12.50)                           14 (70.00)                                       
  Quinupristin/dalfopristin                                         0 (0.00)                            0 (0.00)                                         
  Tetracycline                                                      0 (0.00)                            6 (30.00)                                        
  Teicoplanin                                                       0 (0.00)                            0 (0.00)                                         
  Vancomycin                                                        0 (0.00)                            0 (0.00)                                         

SMZ, sulfamethoxazole; ESBL, extended spectrum beta-lactamases.

[^1]: Contributed equally
